Stoke Therapeutics (STOK) Payables (2018 - 2026)

Stoke Therapeutics' Payables history runs 9 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• In Q1 2026, Payables rose 212.85% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $6.8 million (up 212.85% YoY), while the FY2025 annual figure was $4.9 million, up 97.72% from the prior year.
• Payables was $6.8 million for Q1 2026 at Stoke Therapeutics, up from $4.9 million in the prior quarter.
• In the past five years, Payables ranged from a high of $6.8 million in Q1 2026 to a low of $766000.0 in Q4 2022.
• Historically, Payables has averaged $3.3 million across 5 years, with a median of $3.1 million in 2023.
• Biggest YoY gain for Payables was 274.04% in 2022; the steepest drop was 67.88% in 2022.
• A 5-year view of Payables shows it stood at $766000.0 in 2022, then soared by 121.28% to $1.7 million in 2023, then soared by 47.37% to $2.5 million in 2024, then jumped by 97.72% to $4.9 million in 2025, then soared by 38.47% to $6.8 million in 2026.
• The last three Payables figures came in at $6.8 million (Q1 2026), $4.9 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.